Clarke, N. W., Sydes, M. R., Dearnaley, D., Mason, Malcolm David ![]() |
Official URL: http://dx.doi.org/10.1016/S1569-9056(08)60648-X
Abstract
Most drug trials in prostate cancer (PCa) concentrate on patients withhormone refractory disease. Drugs which work later in the disease may work better still if used earlier. STAMPEDE is an academic, investigator-initiated randomised controlled trial to test six treatment approaches for patients with high-risk localised or metastatic PCa who are commencing long-termhormone therapy (HT).
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Schools > Medicine |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Additional Information: | 23rd Annual Congress of the European Association of Urology |
Publisher: | Elsevier |
ISSN: | 1569-9056 |
Last Modified: | 18 Oct 2022 14:21 |
URI: | https://orca.cardiff.ac.uk/id/eprint/17219 |
Actions (repository staff only)
![]() |
Edit Item |